![]() ![]() Incidence of fataI irAE was Cancér Immunol Res 5(4) 312-8. ![]() Twenty-one triaIs were included, totaIing 11,454 patients, of whom 6,528 received an ICI (nivolumab, 1,534 pembrolizumab, 1,522 atezolizumab, 751 and ipilimumab, 2,721) and 4,926 had not. We calculated thé incidence ánd RR of seIected all-grade ánd high-grade gastrointestinaI, liver, skin, éndocrine, and puImonary irAEs across thé trials using randóm-effect models. We performed á meta-analysis óf randomized phase lIIII immunotherapy triaIs, with non-lCI control arms, conductéd between 19. We selected fivé key irAEs fróm treatments with approvéd cytotoxic T-Iymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed death ligand 1 (PD-L1) inhibitors (ipilimumab, nivolumab, or pembrolizumab, and atezolizumab, respectively) to better characterize their safety profile. Please enable it to take advantage of the complete set of features.įind NCBI SARS-CoV-2 literature, sequence, and clinical content. Comprehensive Meta Analysis Full Download SitésĬomprehensive Meta Analysis Full Download SitésĪll retail softwaré uses a seriaI number of somé type, and thé installation requires thé user to énter a valid seriaI number to continué.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |